Provided by Tiger Fintech (Singapore) Pte. Ltd.

PAVmed

0.6551
-0.0549-7.73%
Post-market: 0.70070.0456+6.96%17:46 EDT
Volume:85.37K
Turnover:57.87K
Market Cap:11.20M
PE:1.32
High:0.7300
Open:0.7300
Low:0.6400
Close:0.7100
Loading ...

Lucid Diagnostics Inc: Qtrly Loss per Share $0.20

THOMSON REUTERS
·
24 Mar

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

THOMSON REUTERS
·
24 Mar

Press Release: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
24 Mar

PAVmed Inc expected to post a loss of 57 cents a share - Earnings Preview

Reuters
·
22 Mar

Lucid Diagnostics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
21 Mar

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (Nccn) Guidelines NOW Include Esophageal Precancer Screening

THOMSON REUTERS
·
20 Mar

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

PR Newswire
·
20 Mar

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PR Newswire
·
18 Mar

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

PR Newswire
·
11 Mar

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

PR Newswire
·
10 Mar

BRIEF-Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Reuters
·
06 Mar

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

THOMSON REUTERS
·
06 Mar

Lucid Diagnostics Prices $15.3 Million Direct Offering

MT Newswires Live
·
04 Mar

Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering

TIPRANKS
·
04 Mar

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

PR Newswire
·
04 Mar

BRIEF-Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21 - SEC Filing

Reuters
·
01 Mar

Renowned Investigators Awarded $8 Million Nih Grant to Study Lucid Diagnostics' Esoguard® in at-Risk Patients Without Symptomatic Gerd

THOMSON REUTERS
·
27 Feb

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

PR Newswire
·
27 Feb

Lucid Diagnostics Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
25 Feb

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire
·
25 Feb